Tag Archives: SYLVANT

First treatment approved for the management of MCD in Europe

First treatment approved for the management of MCD in Europe

Janssen-Cilag International NV announced today that the European Commission (EC) has approved the use of SYLVANT? (siltuximab) for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative.…
Top